On August 24, 2026, IceCure Medical Ltd. announced an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands. The initial term is subject to negotiation of a longer-term agreement. This partnership supports market development and clinical education in a key European market where the independent THERMAC breast cancer trial has advanced to Phase III, highlighting cryoablation's high complete ablation rate. IceCure Medical Ltd. develops minimally-invasive liquid-nitrogen-based cryoablation therapy systems for tumor destruction.
